STAMFORD, Conn. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
STAMFORD, Conn. , July 31, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today
STAMFORD, Conn. , July 23, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today
STAMFORD, Conn. , July 18, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today
STAMFORD, Conn. , July 17, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today
Completed Phase 1 trial establishes Oral KORSUVA tablet strengths for treatment of CKD-associated pruritus STAMFORD, Conn., July 11, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed
-I.V. CR845 achieved statistical significance for the study’s primary endpoint of pain relief over the 0 to 24-hour (AUC 0-24) period post-surgery for combined surgeries at the 1.0 mcg/kg dose (p=0.032)- -I.V. CR845 treatment resulted in statistically significant reductions in the secondary
STAMFORD, Conn. , May 29, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
Cara receives upfront payment of $50 million in cash and an equity investment of $20 million Cara eligible for up to $470 million in regulatory and commercial milestones VFMCRP to commercialize KORSUVA injection worldwide except in the U.S., Japan and South Korea Cara to commercialize KORSUVA
STAMFORD, Conn. , May 14, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced